Clinical Trial Update: Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing cetuximab plus mFOLFOX6 versus mFOLFOX6 alone in patients with RAS/BRAF wild-type, high-risk resectable colorectal liver metastases is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Liver Metastases

Drugs mentioned

• Cetuximab (cetuximab)
• MFOLFOX6

Snippet

Sponsor: Fudan University | Conditions: Colorectal Cancer, Liver Metastases | Phase 3 | Status: NOT_YET_RECRUITING